Zevorcabtagene Autoleucel

泽沃基奥仑赛

Report date: 2024/04/24 14:57:23

Base Information

Drug NameZevorcabtagene Autoleucel
Drug Alias NameBCMA-redirected autologous T cellsZevo-celzevor-cel赛恺泽CT-053-CARsgen
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > Autologous +[4] 
Mechanisms of ActionT lymphocyte replacementsAnti-BCMA
TargetsB-cell maturation protein
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsMultiple Myeloma
Approved Indications in ChinaMultiple Myeloma
Original Approved Country/TerritoryMainland China
Original Approved Date2024/02/23
Country/TerritoryCanadaUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesCarsgen Biomedicine (Shanghai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesZhejiang Neptunus Medicine Co LtdHK inno.N CorporationCarsgen Biomedicine (Shanghai) Co Ltd +[4] 
Inactive CompaniesShanghai Carsgen Pharmaceutical Co Ltd
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBank